W. Kang

605 total citations
24 papers, 492 citations indexed

About

W. Kang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, W. Kang has authored 24 papers receiving a total of 492 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 11 papers in Surgery. Recurrent topics in W. Kang's work include Gastric Cancer Management and Outcomes (13 papers), Colorectal Cancer Treatments and Studies (9 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (6 papers). W. Kang is often cited by papers focused on Gastric Cancer Management and Outcomes (13 papers), Colorectal Cancer Treatments and Studies (9 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (6 papers). W. Kang collaborates with scholars based in South Korea, United States and Japan. W. Kang's co-authors include L Whitesell, Farzaneh Pirnia, Wen‐Ning Fang, Maria Tsokos, Oliver Sartor, Yung‐Jue Bang, Mahn Joon Ha, P Nguyen, Chul Won Jung and Ho Yeong Lim and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

W. Kang

22 papers receiving 487 citations

Peers

Countries citing papers authored by W. Kang

Since Specialization

Citations

This map shows the geographic impact of W. Kang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. Kang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. Kang more than expected).

Fields of papers citing papers by W. Kang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W. Kang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. Kang. The network helps show where W. Kang may publish in the future.

Co-authorship network of co-authors of W. Kang

This figure shows the co-authorship network connecting the top 25 collaborators of W. Kang. A scholar is included among the top collaborators of W. Kang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W. Kang. W. Kang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Investigation of Resonance Avoidance Method for Vacuum Cleaner 2023 ·SHILAP Revista de lepidopterología ·(unknown), Ji‐Min Kim, (unknown), W. Kang, Sunghyuk Park	0
2	Randomized phase III ANGEL study of rivoceranib (apatinib) + best supportive care (BSC) vs placebo + BSC in patients with advanced/metastatic gastric cancer who failed ≥2 prior chemotherapy regimens 2019 ·Annals of Oncology ·Yoon‐Koo Kang, W. Kang, Maria Di Bartolomeo, Ian Chau, Harry H. Yoon, Stefano Cascinu, Min‐Hee Ryu, (unknown), K.-W. Lee, Sang Cheul Oh, Atsuo Takashima, Anna Kryzhanivska, Yee Chao, Vladimir Vladimirov, Ludovic Evesque, Michael Schenker, (unknown), (unknown), Lucjan Wyrwicz, Narikazu Boku	47
3	A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer 2015 ·British Journal of Cancer ·Seong Hoon Lim, Tae Won Kim, (unknown), Seung Woo Han, Kyung‐Ha Lee, Hye Jin Kang, (unknown), (unknown), Hyo Song Kim, (unknown), (unknown), (unknown), (unknown), (unknown), Ho Yeong Lim, Sung‐Hoon Jung, W. Kang	65
4	Randomized Phase Ii Study of Capecitabine and Cisplatin with or Without Sorafenib in Patients with Metastatic Gastric Cancer: Stargate Study 2014 ·Annals of Oncology ·Yoon‐Koo Kang, (unknown), Lin Shen, Kun‐Huei Yeh, Young Seon Hong, (unknown), Sheng Yang, D.B. Shin, Dae Young Zang, W. Kang, Ik‐Joo Chung, Yeul Hong Kim, Baek‐Yeol Ryoo, (unknown), (unknown), (unknown)	16
5	A phase I study of neoadjuvant chemoradiotherapy with S-1/oxaliplatin in patients with gastric cancer. 2011 ·Journal of Clinical Oncology ·(unknown), (unknown), Do Hoon Lim, (unknown), (unknown), Jeong Youp Park, (unknown), Ho Yeong Lim, W. Kang	1
6	The role of oophorectomy for colon cancer with ovarian metastasis 2009 ·Journal of Clinical Oncology ·Sang‐Hyun Lee, Jung Jae Lee, Hyun Kyong Ahn, Jinny Park, (unknown), K. Park, Ho Yeong Lim, W. Kang, (unknown), Yongsup Park	1
7	Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer 2009 ·Journal of Clinical Oncology ·Seong Yoon Yi, (unknown), Jin Hee Lee, (unknown), (unknown), (unknown), W. Kang, (unknown), (unknown), (unknown)	4
8	6508 A randomized phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer (AGC): a preliminary safety results 2009 ·European Journal of Cancer Supplements ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), W. Kang	1
9	Gastric GIST: A single institutional retrospective experience with surgical treatment for primary disease 2007 ·European Journal of Surgical Oncology ·Ji Yeong An, Min Gew Choi, Jung Hyun Noh, (unknown), W. Kang, (unknown), (unknown)	30
10	3542 POSTER Preliminary results from a phase II study of sunitinib as second-line treatment for advanced gastric cancer 2007 ·European Journal of Cancer Supplements ·(unknown), (unknown), W. Kang, Narikazu Boku, Heewon Chung, Jennifer Tursi, M.J. Lechuga, Lev Verkh, Richard C. Chao, Alberto Sobrero	3
11	A multi-center phase II study of S-1 plus paclitaxel as first-line therapy in patients with advanced or relapsed gastric cancer 2007 ·Journal of Clinical Oncology ·(unknown), (unknown), Hyun Cheol Chung, (unknown), Haiping Song, In Sook Woo, (unknown), W. Kang, (unknown), (unknown)	2
12	Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer 2007 ·Journal of Clinical Oncology ·(unknown), Seong Yoon Yi, Hong-Sik Kim, (unknown), In Gyu Hwang, Sejung Park, (unknown), Jinny Park, Ho Yeong Lim, W. Kang	0
13	Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma 2006 ·Annals of Oncology ·(unknown), W. Kang, (unknown), Sung Yong Oh, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	26
14	A multicenter phase II study of pemetrexed and cisplatin in patients with advanced gastric cancer (AGC) 2006 ·Journal of Clinical Oncology ·Yung‐Jue Bang, (unknown), Hyun Cheol Chung, W. Kang, (unknown), Sheng Yang, (unknown), (unknown), (unknown), Jorge Otero	1
15	Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma 2005 ·Journal of Clinical Oncology ·Jung Ho Kim, (unknown), Chul Won Jung, (unknown), Kyu Hong Kim, W. S. Kim, (unknown), Young‐Hyuck Im, W. Kang, K. Park	30
16	A phase II trial of gemcitabine plus cisplatin (GP) in patients with inoperable biliary tract cancer (BTC) 2005 ·Journal of Clinical Oncology ·(unknown), W. Kang, (unknown), (unknown), Myung‐Ju Ahn, (unknown), N. S. Lee, Ho Yeong Lim, (unknown), (unknown)	2
17	Phase II study of docetaxel combined with cisplatin in advanced gastric cancer 2005 ·Journal of Clinical Oncology ·(unknown), (unknown), Chang‐Won Lee, (unknown), (unknown), (unknown), S. H. Lee, W. Kang, K. Park, (unknown)	1
18	Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer 2004 ·British Journal of Cancer ·(unknown), W. Kang, Jinny Park, H. Y. Kim, (unknown), (unknown), (unknown), Kihyun Kım, Chul Won Jung, Y. S. Park, (unknown), (unknown), (unknown)	21
19	Brief refeeding rapidly reverses dietary restriction‐induced nuclear factor‐kappaB downregulation in peritoneal resident cells 2003 ·Journal of Parenteral and Enteral Nutrition ·W. Kang, Hideki Saito, Kazuhiko Fukatsu, Hirokazu Nagawa, Shigeo Ikeda	5
20	Oral omega-3 polyunsaturated fatty acids (N3PUFA) and arginine supplementation modulate peritoneal resident cell nuclear factor kappa B (NFkappaB) activity 2003 ·Clinical Nutrition ·W. Kang, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact